Overview Dividends

(INMD) InMode - Ratings and Ratios

Exchange: NASDAQ • Country: Israel • Currency: USD • Type: Common Stock • ISIN: IL0011595993

RF, Minimally Invasive, Lasers, Hands-Free

INMD EPS (Earnings per Share)

EPS Growth (3Y CAGR): -64.12%
EPS Trend (3Y Correlation): -70.7%

INMD Revenue

Revenue Growth (3Y CAGR): -8.27%
Revenue Trend (3Y Correlation): -60.3%

Description: INMD InMode August 28, 2025

InMode Ltd (NASDAQ:INMD) is an Israeli‑based public company operating in the Health Care Equipment sub‑industry, focused on minimally invasive aesthetic and medical devices that use proprietary radio‑frequency (RF) technology.

The firm’s market valuation sits just under $1 billion, with a trailing P/E of roughly 6× and a forward P/E near 9×, indicating a low price relative to earnings and modest expectations for near‑term earnings growth. Return on equity exceeds 26%, reflecting efficient capital deployment and high profitability on a lean balance sheet.

Key performance indicators include double‑digit revenue growth over the past three fiscal years, driven by expanding U.S. clinic adoption, international market penetration, and a consumables business that generates recurring cash flow. Gross margins consistently hover around 80%, while operating cash flow conversion remains strong, supporting ongoing R&D investment and strategic acquisitions without reliance on external financing.

Primary economic drivers are the rising demand for elective cosmetic procedures, demographic shifts favoring younger consumers with disposable income, and the company’s ability to secure FDA clearances for new device platforms. Competitive pressures stem from other aesthetic device manufacturers and the broader consumer‑discretionary cycle, making macro‑economic confidence and regulatory timelines critical to sustaining growth.

INMD Stock Overview

Market Cap in USD	968m
Sub-Industry	Health Care Equipment
IPO / Inception	2019-08-08

INMD Stock Ratings

Growth Rating	-71.9%
Fundamental	61.4%
Dividend Rating	-
Return 12m vs S&P 500	-30.4%
Analyst Rating	3.43 of 5

INMD Dividends

Currently no dividends paid

INMD Growth Ratios

Growth Correlation 3m	69.8%
Growth Correlation 12m	-66.8%
Growth Correlation 5y	-79.6%
CAGR 5y	-23.63%
CAGR/Max DD 3y (Calmar Ratio)	-0.33
CAGR/Mean DD 3y (Pain Ratio)	-0.51
Sharpe Ratio 12m	0.75
Alpha	-53.49
Beta	2.093
Volatility	44.93%
Current Volume	692.3k
Average Volume 20d	653.5k
Stop Loss	14.1 (-4%)
Signal	-0.01

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (178.7m TTM) > 0 and > 6% of Revenue (6% = 24.1m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA -4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 142.5% (prev 178.9%; Δ -36.38pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 104.8m <= Net Income 178.7m (YES >=105%, WARN >=100%)

Net Debt (-210.1m) to EBITDA (123.4m) ratio: -1.70 <= 3.0 (WARN <= 3.5)

Current Ratio 9.60 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (63.6m) change vs 12m ago -25.91% (target <= -2.0% for YES)

Gross Margin 79.98% (prev 82.27%; Δ -2.29pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 51.21% (prev 48.45%; Δ 2.76pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.81 (EBITDA TTM 123.4m / Interest Expense TTM -21.1m) >= 6 (WARN >= 3)

Altman Z'' 21.87

(A) 0.81 = (Total Current Assets 638.8m - Total Current Liabilities 66.5m) / Total Assets 708.3m

(B) 1.23 = Retained Earnings (Balance) 874.7m / Total Assets 708.3m

warn (B) unusual magnitude: 1.23 — check mapping/units

(D) 10.94 = Book Value of Equity 874.6m / Total Liabilities 79.9m

Total Rating: 21.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.42

1. Piotroski 4.0pt = -1.0

2. FCF Yield 22.49% = 5.0

3. FCF Margin 25.94% = 6.49

4. Debt/Equity 0.01 = 2.50

5. Debt/Ebitda -1.70 = 2.50

6. ROIC - WACC (= 1.42)% = 1.78

7. RoE 26.59% = 2.22

8. Rev. Trend -60.30% = -4.52

9. EPS Trend -70.73% = -3.54

What is the price of INMD shares?

As of November 04, 2025, the stock is trading at USD 14.69 with a total of 692,338 shares traded.
Over the past week, the price has changed by -6.13%, over one month by -3.04%, over three months by +4.41% and over the past year by -15.48%.

Is InMode a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, InMode is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 61.42 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of INMD is around 10.99 USD . This means that INMD is currently overvalued and has a potential downside of -25.19%.

Is INMD a buy, sell or hold?

InMode has received a consensus analysts rating of 3.43. Therefor, it is recommend to hold INMD.

Strong Buy: 1
Buy: 1
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the INMD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	16.7	13.3%
Analysts Target Price	16.7	13.3%
ValueRay Target Price	12.8	-12.7%

INMD Fundamental Data Overview October 27, 2025

Market Cap USD = 967.7m (967.7m USD * 1.0 USD.USD)
P/E Trailing = 6.4328
P/E Forward = 8.6957
P/S = 2.4099
P/B = 1.555
P/EG = 2.9004
Beta = 2.093
Revenue TTM = 401.6m USD
EBIT TTM = 122.7m USD
EBITDA TTM = 123.4m USD
Long Term Debt = 6.10m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.02m USD (from shortTermDebt, last fiscal year)
Debt = 6.10m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -210.1m USD (from netDebt column, last quarter)
Enterprise Value = 463.2m USD (967.7m + Debt 6.10m - CCE 510.7m)
Interest Coverage Ratio = -5.81 (Ebit TTM 122.7m / Interest Expense TTM -21.1m)
FCF Yield = 22.49% (FCF TTM 104.2m / Enterprise Value 463.2m)
FCF Margin = 25.94% (FCF TTM 104.2m / Revenue TTM 401.6m)
Net Margin = 44.50% (Net Income TTM 178.7m / Revenue TTM 401.6m)
Gross Margin = 79.98% ((Revenue TTM 401.6m - Cost of Revenue TTM 80.4m) / Revenue TTM)
Gross Margin QoQ = 79.97% (prev 78.22%)
Tobins Q-Ratio = 0.65 (Enterprise Value 463.2m / Total Assets 708.3m)
Interest Expense / Debt = 53.89% (Interest Expense 3.29m / Debt 6.10m)
Taxrate = 13.58% (4.20m / 30.9m)
NOPAT = 106.0m (EBIT 122.7m * (1 - 13.58%))
Current Ratio = 9.60 (Total Current Assets 638.8m / Total Current Liabilities 66.5m)
Debt / Equity = 0.01 (Debt 6.10m / totalStockholderEquity, last quarter 628.4m)
Debt / EBITDA = -1.70 (Net Debt -210.1m / EBITDA 123.4m)
Debt / FCF = -2.02 (Net Debt -210.1m / FCF TTM 104.2m)
Total Stockholder Equity = 672.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 25.23% (Net Income 178.7m / Total Assets 708.3m)
RoE = 26.59% (Net Income TTM 178.7m / Total Stockholder Equity 672.1m)
RoCE = 18.09% (EBIT 122.7m / Capital Employed (Equity 672.1m + L.T.Debt 6.10m))
RoIC = 15.07% (NOPAT 106.0m / Invested Capital 703.8m)
WACC = 13.64% (E(967.7m)/V(973.8m) * Re(13.73%) + (debt cost/tax rate unavailable))
Discount Rate = 13.73% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -13.90%
[DCF Debug] Terminal Value 59.70% ; FCFE base≈129.6m ; Y1≈126.3m ; Y5≈127.1m
Fair Price DCF = 16.99 (DCF Value 1.07b / Shares Outstanding 63.2m; 5y FCF grow -3.68% → 3.0% )
EPS Correlation: -70.73 | EPS CAGR: -64.12% | SUE: -4.0 | # QB: 0
Revenue Correlation: -60.30 | Revenue CAGR: -8.27% | SUE: 0.20 | # QB: 0

Additional Sources for INMD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle